Provided by Tiger Trade Technology Pte. Ltd.

HCW Biologics Inc.

1.71
-0.0400-2.29%
Post-market: 1.710.00000.00%19:59 EDT
Volume:48.41K
Turnover:83.99K
Market Cap:3.14M
PE:-0.06
High:1.82
Open:1.77
Low:1.71
Close:1.75
52wk High:29.28
52wk Low:1.50
Shares:1.84M
Float Shares:1.65M
Volume Ratio:0.02
T/O Rate:2.93%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-27.1846
EPS(LYR):-63.7804
ROE:-151.36%
ROA:-13.88%
PB:0.42
PE(LYR):-0.03

Loading ...

Why Is Penny Stock HCW Biologics (HCWB) Up Today?

TIPRANKS
·
May 16

NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 09:33 AM

Reuters
·
May 15

Top Premarket Gainers

MT Newswires Live
·
May 15

Dawson Geophysical (DWSN) Stock Surges Over 16% Overnight: Why Is It Moving?

Benzinga Earnings
·
May 15

HCW Biologics (HCWB) Stock Is Trending Overnight — Here's Why It Moved Over 122% In After-Hours Session

Benzinga Earnings
·
May 15

HCW Biologics swings to Q1 profit of $3.47 million; revenue rises to $6.54 million

Reuters
·
May 15

HCW Biologics Q1 revenue surges on licensing deal

Reuters
·
May 15

HCW Biologics Q1 EPS $0.37 Beats $(0.44) Estimate, Sales $6.543M Up From $5.065K YoY

Benzinga Earnings
·
May 15

HCW Biologics: on Track to Report Phase 1 HCW9302 Alopecia Data in H1 2026

THOMSON REUTERS
·
May 15

HCW Biologics, Inc Q1 Basic EPS USD 0.37

THOMSON REUTERS
·
May 15

Press Release: HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results

Dow Jones
·
May 15

HCW Biologics discovers HCW11-040 prevents bronchopulmonary dysplasia

TIPRANKS
·
May 14

BRIEF-HCW Biologics Discovers That HCW11-040 Prevents Bronchopulmonary Dysplasia During IND-Enabling Studies

Reuters
·
May 14

HCW Biologics Inc - Expects to Complete Ind-Enabling Studies in H2 2027 and File Ind Application for HCW11-040

THOMSON REUTERS
·
May 14

HCW Biologics Discovers that HCW11-040 Prevents Bronchopulmonary Dysplasia (BPD) During IND-Enabling Studies

GlobeNewswire
·
May 14

HCW Biologics Announces Adjournment of Special Meeting of Stockholders Due to Lack of Quorum

GlobeNewswire
·
May 01

HCW Biologics Inc - Agreement to Commence on or About May 1, 2026, Subject to Public Offering Close - SEC Filing

THOMSON REUTERS
·
Apr 30

HCW Biologics Inc - on April 25, Co to Enter $2.5 Mln Marketing Consulting Agreement With I.r. Agency Llc - SEC Filing

THOMSON REUTERS
·
Apr 30

HCW Biologics to file IND for HCW11-018b in first half of 2027

TIPRANKS
·
Apr 27

BRIEF-Hcw Biologics Delivers A Major Update For Its T-Cell Engager Program Revealing Mechanism Of Action

Reuters
·
Apr 27